Ozempic may gift US a $3 trln benefit
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.
By Robert Cyran
NEW YORK, July 16 (Reuters Breakingviews) -The United States spends 17% of its gross domestic product on healthcare, about twice as much as the average OECD country, according to the Commonwealth Fund. Can weight loss drugs like Ozempic help shrink that? According to a recent study, the answer is probably no. But other medical breakthroughs have temporarily changed the course of U.S. spending. There’s hope that the fattest developed country in the world can stall growth for good.
A government estimate in June concluded spending will rise 5.6% annually until 2032. The Centers for Medicare and Medicaid Services think it will grow faster than the overall economy thanks to the aging population and poor healthcare productivity, among other things. At $22 trillion – the outlay the organization thinks the country will make by 2032 – it will account for almost 20% of GDP.
In the long arc of the United States' spending on medical treatments, that fits with the trend. Healthcare as a percentage of GDP tripled between 1960 and 2010. The hitch is that, for the last decade or so, the relative figure hasn’t budged.
Obvious suspects don’t fully explain the current slowdown. The Affordable Care Act probably helped. But medical spending growth was slowing prior to its 2010 passage, and major parts of the ACA weren’t phased in until 2016. Other effects, like the pandemic, could be transitory.
Other reasonable explanations offer some reasons for optimism. Harvard professor Joseph Newhouse pointed out people have become willing to pay for medical advances, which improve welfare. People still swallow aspirin, but now also take $100,000 cancer treatments. The onset of key drugs may have also helped. Cardiovascular spending fell dramatically from 2005 to 2012, and Harvard Professor David Cutler attributes half of that reduction to drugs such as statins.
The effects of obesity treatments from Eli Lilly LLY.N and Novo Nordisk NOVOb.CO might be similar. With list prices around $1,000 a month, the use of the drug in non-diabetic patients is probably not cost-effective. Nonprofit KFF, however, estimated the average obese health plan member’s medical spend in 2021 was $12,588 or 2.7 times as much as a non-obese member. If the net cost of the drug could be lowered to $500 a month and this reduced patients’ medical costs to that of non-obese people, that would save about 18% per obese patient, or roughly $250 billion annually based on the current population. And that could underestimate the savings. If healthcare expenditures were capped at 17% of GDP, then that would save the U.S. an estimated $2.6 trillion by 2032.
Of course, thinner patients may incur more or different medical costs. But obesity is associated with most major causes of U.S. death and illness. An ounce of cure is worth a lifetime of expense.
Follow @rob_cyran on X
CONTEXT NEWS
The U.S. Centers for Medicare and Medicaid Services Office of the Actuary releases projections for national health expenditure on June 12. They project average annual growth of 5.6% from 2023 to 2032. That is estimated to grow faster than annual growth in gross domestic product, taking health expenditure from 17.3% in 2022 to 19.7% of GDP in 2032.
Graphic: Obesity drugs may bend healthcare expenditure curve Obesity drugs may bend healthcare expenditure curve https://reut.rs/3zkxa7W
Editing by Lauren Silva Laughlin and Sharon Lam
Dernières actualités
Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.
Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.
Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.